Overview
XLO market data
Price History
XLO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.19 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.11 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -58.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.47 – $12.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $54.1M · P/B 0.95 · P/S 1.01.
Company News
Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M EstimateBenzinga · Aug 12, 2026, 11:37 AM
8-K filing — Xilio Therapeutics, Inc. (XLO)SEC EDGAR · Aug 12, 2026, 11:35 AM